On 8 December 2023, the U.S. Food and Drug Administration approved Casgevy for sickle cell disease, marking a historic milestone: it became the first FDA-authorised treatment to use CRISPR/Cas9 genome editing. On the same day, the agency also approved Lyfgenia, another gene therapy for the disease using a different approach.
The decision mattered because CRISPR had rapidly become one of molecular biology’s most promising technologies, but regulatory approval turned a scientific possibility into clinical medicine. Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, was initially authorised in the United States for patients aged 12 and older with recurrent vaso-occlusive crises.
How the therapy works
Sickle cell disease is caused by a mutation affecting haemoglobin. Red blood cells become rigid and sickle-shaped, potentially blocking small blood vessels, reducing oxygen delivery and causing severe pain and organ damage.
Casgevy does not directly repair the disease-causing mutation. Instead, blood-forming stem cells are collected from the patient and edited in a laboratory with CRISPR/Cas9. The process targets a genetic regulator so that the cells produce more fetal haemoglobin, a form normally present early in life that can compensate for the effects of sickle haemoglobin.
The edited cells are then infused back into the patient. Before infusion, patients undergo conditioning treatment, generally chemotherapy, to make room in the bone marrow for the modified cells. This makes Casgevy an intensive, highly specialised therapy rather than a simple outpatient medicine.
Why CRISPR changes the model
Traditional gene therapies often add a functional gene through viral vectors. CRISPR makes it possible to edit specific DNA sequences with greater precision. That creates opportunities for inherited diseases, cancer and other conditions in which carefully changing gene expression can produce a therapeutic effect.
Casgevy’s success does not mean every CRISPR application is ready for routine care. Each indication requires its own evidence on efficacy, safety and durability. Regulators also need long-term monitoring for unintended edits and other consequences of genome manipulation.
Personalised treatment means complex logistics
The manufacturing process begins with each individual patient. Cells must be collected, shipped to specialised facilities, edited, tested and returned to the clinical centre. This is fundamentally different from a conventional drug manufactured in large batches.
Manufacturing capacity, laboratory quality, logistics, clinical coordination and turnaround times therefore become part of real-world therapeutic performance. A biological technology can be extraordinary and still have limited impact if health systems cannot deliver it to eligible patients.
The access challenge
Cell and gene therapies are expensive and require highly specialised centres. That raises questions of affordability for insurers and public health systems, as well as global equity. Sickle cell disease affects many people in regions with far fewer health resources than the United States or Europe.
The scientific breakthrough therefore comes with a second challenge: making precision medicine easier to manufacture, less expensive and more widely accessible. Better editing tools, automation and more distributed manufacturing could reduce some barriers, but those changes will take time.
From discovery to therapeutic platform
CRISPR has already become core infrastructure in biomedical research. Casgevy’s approval added a crucial proof point: genome editing can pass through clinical trials, regulatory scrutiny and manufacturing requirements to become a real treatment.
The significance goes beyond one therapy for sickle cell disease. CRISPR is becoming a platform that may be adapted to many conditions. How quickly that happens will depend on improvements in safety, manufacturing simplicity and affordability while preserving the rigorous controls required when human cells are edited at the genetic level.
